

Euro-DyMA pharma's day

*Lindenberg Cultural Center
Ridderstraat 23,
Nijmegen*

April 9th, 9.00AM, 1.30PM

- 9.00 Welcome address and news from Euro-DyMA, **Alain Geille, Pr. Benedikt Schoser,**
- 9.15 FREEDOM-DM1: A Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PGN-EDODM1 in Adults with Myotonic Dystrophy Type 1 (DM1), **Jane Larkindale,** Pepgen Inc,
- 9.45 AMO-02 for Myotonic Dystrophy – An Update, **Emily Fantelli,** AMO-Pharma,
- 10.15 ATX-01, a Novel AntimiR-23b Investigational Oligonucleotide to Treat Myotonic Dystrophy (DM), **Judy Walker, MD, FRCPC,** Chief Medical Officer, Arthex Biotech
- 10.45 Transforming Myotonic Dystrophy, Global Phase 3 HARBOR Study & Long-term MARINA-OLE Study Results, **Li-Jung-Tai,** Avidity Biosciences,
- 11.15 Achieving the Promise of FORCE to Deliver for Patients, **Ash Dugar,** Chief Medical Affairs Officer, Dyne Therapeutics,
- 11.45 Conclusions and adjourn
- 12.00 Lunch
- 13.30 End